64 results about "Endocrine therapy" patented technology

The invention discloses a prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence. The prostate cancer endocrine therapy drug resistance prediction system comprises a data acquisition and preprocessing module, a single omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. Multi-omics data of a patient is collected and preprocessed, data representations of omics data of different labels are generated by using priori knowledge, and an optimal single-omics prediction model is matched for the omics data of different labels based on the data representations after knowledge enhancement. And constructing a multi-omics prediction model of the prostatic cancer endocrine treatment drug resistance by using the optimal single-omics prediction model corresponding to the different label medical data by adopting Stacking, predicting the drug resistance risk of the patient within a preset time, outputting an early warning, and adjusting the treatment scheme of the patient according to the drug resistance risk. According to the method, the multi-omics data are integrated, the accurate multi-omics prediction model for the drug resistance of the endocrine therapy of the prostate cancer is constructed, and the accuracy and clinical applicability of drug resistance prediction are improved.

The utility model provides an endocrine therapy medicine fumigation device, which belongs to the technical field of medicine fumigation and comprises a fumigator body. The net rack protection plate is positioned in the fumigator body; the two limiting blocks are fixedly connected to the inner walls of the two sides of the fumigator body; the medicine fumigation storage net is slidably connected to the interiors of the two limiting blocks, the internal secretion treatment medicine fumigation equipment can achieve effective fumigation and delivery of internal secretion medicine, through the slidable medicine fumigation storage net, the placement position of the medicine can be easily adjusted according to needs, and the heating degree and fumigation concentration of the medicine can be conveniently controlled; through the design of the first baffle and the second baffle, the release speed of the medicine can be effectively controlled, it is ensured that the medicine is evenly distributed in the fumigation process, and the treatment effect is improved.

The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent and / or a CDK4 / 6 inhibitor.

The invention provides a traditional Chinese medicine preparation for treating climacteric syndrome in breast cancer endocrine therapy, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine preparation comprises 9-12 g of radix bupleuri, 9-15 g of scutellaria baicalensis, 9-15 g of rhizoma pinelliae preparata, 15-30 g of codonopsis pilosula, 9-15 g of cassia twig, 9-15 g of radix paeoniae alba, 9-15 g of calcined dragon bone, 9-15 g of calcined oyster shell, 15-30 g of rhizoma acori graminei, 9-15 g of radix curcumae, 9-15 g of roasted turtle shell, 9 g of ginger and 9 g of jujube. The traditional Chinese medicine preparation can effectively relieve symptoms such as chest and hypochondrium distension and stuffiness, depression, dysphoria and other emotion regulation, hypochondrium pain and the like of patients with breast cancer endocrine therapy climacteric syndromes.

The present disclosure relates to methods of treating breast cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a radiopharmaceutical compound having a GRPR antagonist moiety, such as [177Lu] Lu-NeoB, in combination with a CDK4 / 6 inhibitor, such as ribociclib, and a therapeutically effective amount of an endocrine therapy, such as fulvestrant.

The invention discloses an application of a PGK1 inhibitor in preparation of a medicine for treating MYC (myelodysplastic cancer) oncogene amplification type prostate cancer, it is found for the first time that PGK1 is a stable target for patent medicine, the PGK1 inhibitor NG-52 can effectively inhibit growth of MYC oncogene amplification type prostate cancer cells, and the target targets a glycolytic pathway, has small influence on aerobic respiratory metabolism of normal cells in a body, and can be used for preparing a medicine for treating MYC oncogene amplification type prostate cancer. The safety is higher; the mechanism of the target is different from that of current advanced prostate cancer chemotherapy drugs and endocrine therapy drugs, and the target has great potential of combined treatment with current first-line drugs, is easy to popularize and use clinically, and provides better prognosis for MYC gene amplification type prostate cancer patients.

The present disclosure relates to a panel of ER regulated genes and method for using the panel for monitoring the response of an individual having cancer to treatment with amcenestrant, the method comprising determining a first ER activity score from a sample from the individual at a first time point before treatment with amcenestrant using the panel, then determining a second ER activity score from a sample from the individual at a second time point following administration of amcenestrant using the panel, and comparing the first ER activity score with the second ER activity score, wherein a decrease in the second ER activity score relative to the first ER activity score is predictive of target engagement of amcenestrant.

The present invention discloses an adjuvant treatment of node-positive, carly stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) breast cancer comprising administering an effective amount of an endocrine therapy in combination with an effective amount of abemaciclib or a pharmaceutically acceptable salt thereof.

The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.

Provided herein are methods of determining tumoral sensitivity to hormonal (endocrine) therapy based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index), and may have additional consideration for the proportion of ER gene (ESR1) RNA transcripts that contain a mutation relative to the value of the SETER / PR index. Further provided are methods of treating breast cancer patients determined to be sensitive to an endocrine therapy by the SETER / PR index.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The present invention relates to the field of medicine, and discloses a novel endocrine therapy resistance marker for advanced prostate cancer and its application, wherein the marker is DENND3. The present invention first discovered that the expression level of the DENND3 gene in prostate cancer abiraterone-resistant cells is significantly higher than that in parental prostate cancer cells. Therefore, the determination of the expression level of the DENND3 gene can be used as a basis for judging the drug resistance / sensitivity of the user to abiraterone; the DENND3 gene-specific siRNAs provided by the present invention can efficiently inhibit or knock down the expression of the DENND3 gene in target cells, thereby promoting cell apoptosis, inhibiting the proliferation of abiraterone-resistant prostate cancer cells, and further inhibiting the growth of prostate cancer cells. Therefore, it can be used to prepare a drug that improves the resistance of prostate cancer to abiraterone, and has great clinical and economic value in the treatment of prostate cancer.

Small molecule ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells are disclosed. In one embodiment, the small molecule biomodulator has increased therapeutic utility because of an increased ability to kill therapy-resistant cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen, and fulvestrant / ICI). The small molecule biomodulators not only inhibit proliferation of the cancer cells but kills them, which prevents reactivation of tumors years later. Compounds of the invention, such as ErSO-TFPy, are effective for treating ERα positive cancers such as breast cancer, ovarian cancer, uterine cancer, cervical carcinoma, endometrial cancer, and the like.

The utility model relates to the technical field of medicine fumigation equipment, in particular to endocrine treatment medicine fumigation equipment which comprises a treatment box, the outer wall of one side of the treatment box is open, a drawer is installed on the inner wall of the bottom of the treatment box in a sliding mode, and the same partition plate is fixedly installed on the inner walls of the two sides of the treatment box. The partition plate is located above the treatment box, the same mounting frame is slidably mounted on the inner walls of the two sides of the treatment box, an air driving mechanism is arranged in the mounting frame, and the air driving mechanism comprises a plurality of exhaust fans. According to the medicine aromatherapy device, the defects in the prior art are overcome, under the matching action of the exhaust fans and the like, the multiple exhaust fans are turned on and rotate, so that aromatherapy steam in the drawer can be exhausted through the partition plate and the air outlet in the treatment box, medicine aromatherapy steam treatment is carried out on a patient, and the medicine aromatherapy effect is good. Therefore, the steam exhaust efficiency is improved, long treatment time is not needed, and the treatment effect is good.

The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to extended treatment and cancer-free survival in a patient. In particular, the disclosure includes the identities of genes that are expressed in correlation with benefit in a switch in endocrine therapy used to treat a patient. The levels of gene expression are disclosed as a molecular index for predicting clinical outcome, and so prognosis, for the patient. The disclosure further includes methods for predicting cancer recurrence, and / or predicting occurrence of metastatic cancer, after initial treatment with an anti-estrogen agent. The disclosure further includes methods for determining or selecting the treatment of a subject based upon the likelihood of life expectancy, cancer recurrence, and / or cancer metastasis.

The invention relates to the technical field of traditional Chinese medicine equipment, in particular to a traditional Chinese medicine filtering device for internal Chinese medicine endocrine therapy, which comprises a primary filter with a cavity structure, a peristaltic filter element arranged in the primary filter, a liquid inlet arranged at the top of the primary filter and a discharge port arranged at the bottom of the primary filter, electric control valves are respectively arranged in the medicine inlet, the first slag discharge port and the discharge port; the primary filter is also provided with a filter element driver; the fine filters are communicated with the discharging opening through electric control valves, each fine filter is of a cavity structure, a ceramic separation membrane is arranged in each fine filter, and a fine filter opening is formed in the bottom of each fine filter; the molecular sieve is of a longitudinal cavity structure, the top of the molecular sieve is provided with a high-pressure connector, the high-pressure connector is communicated with the fine filtration opening through a high-pressure pump, and the molecular sieve is provided with a medicine outlet. Through a multi-stage precise separation technology and a dynamic anti-blocking design, the purification problem of the traditional Chinese medicine decoction is systematically solved, and the traditional Chinese medicine stability of endocrine disease patients is ensured.

The invention discloses an application of LINC02568 as a target in preparation of an ER < + > breast cancer treatment kit. The reagent targeting LINC02568 can effectively inhibit in-vitro growth of ER < + > breast cancer cells and in-vivo tumor formation, and can be combined with an endocrine therapeutic drug or a small-molecule inhibitor targeting CA12 to achieve a synergistic inhibition effect on growth of cells and tumors.

Methods of treatment, methods of detection, and kits associated with ERα+ cancer, such as ERα+ breast cancer, are disclosed herein. The methods and kits disclosed herein can assist physicians in relieving patient suffering by identifying cancer estrogen receptor status, and identifying appropriate therapeutic regimens in an individualized manner.

The invention discloses a multi-targeting photothermal-photodynamic-endocrine three-mode synergistic breast cancer treatment nano-drug and application thereof, and relates to the technical field of biology and new medicine. Growth and metastasis of breast cancer cells are effectively inhibited through the synergistic effect of three modes of photo-thermal, photodynamic and endocrine therapy, the amphiphilic polymer designed based on Tcpp (tetracarboxylphenylporphyrin) can be self-assembled to form a nanoscale hollow regular sphere, and by means of the high permeability and retention effect (EPR effect) of a tumor site, the tumor site can be effectively inhibited, and the tumor site can be effectively inhibited. The efficient accumulation of the medicine in the tumor tissue is realized; the prodrug BHP is combined with a photo-thermal group and palbociclib, so that the synergistic interaction of multiple action mechanisms is realized, and the treatment effect is improved. The nano-drug prepared by the invention has good safety and biocompatibility, shows a remarkable anti-tumor effect in a tumor-bearing nude mouse model, and provides a brand new strategy and thought for treatment of breast cancer.

The invention belongs to the technical field of prostate cancer diagnosis, and particularly relates to serum 7-dehydrocholesterol as a prostate cancer metastasis and endocrine treatment drug resistance diagnosis marker and application thereof. 7-dehydrocholesterol provided by the invention has different levels in human prostate cancer cell lines such as LNCaP, Du145, PC3 and the like, and is abnormally increased in PC3, so that the 7-dehydrocholesterol can be used as a drug resistance diagnosis marker for prostate cancer metastasis and endocrine therapy; the reagent composition capable of specifically recognizing 7-dehydrocholesterol and generating detectable signals can be used for preparing a prostate cancer detection kit; the 7-dehydrocholesterol provided by the invention has non-invasive, non-invasive and efficient effects as a diagnostic marker, and solves the technical problem of lack of a prostate cancer diagnostic marker in the prior art.

To provide a novel therapeutic method exhibiting significantly excellent antitumor effect to a tumor treatable with endocrine therapy by using a FGFR inhibitor.SOLUTION: Provided is a novel treatment method for cancer tumors to which endocrine therapy is to be applied, using an FGFR inhibitor (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition comprising the above compound or a pharmaceutically acceptable salt thereof for use in treatment and / or prevention of tumors to which endocrine therapy is applicable, as well as related compounds, uses, methods, and combinations.SELECTED DRAWING: None

The invention discloses a primer and probe combination for detecting ESR1 gene drug-resistant mutation sites based on a digital PCR single tube and application of the primer and probe combination, and belongs to the technical field of molecular detection, sequences of primers are shown as SEQ ID NO.1-2, sequences of probes are shown as SEQ ID NO.3-4, and 5'ends of the two probes are marked with different fluorophores. According to the present invention, with the primer probe combination, the high-sensitivity and rapid detection of the common nine drug-resistant related mutation sites such as L536H, L536Q, L536R, L536P, Y537S, Y537C, Y537N, Y537D and D538G of the ESR1 gene in the breast cancer through the single tube can be achieved, such that the ESR1 gene detection efficiency is substantially improved, and the detection cost is reduced so as to guide the endocrine treatment of the breast cancer.

This disclosure relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) disclosed herein, and a monoclonal antibody or an antibody-drug conjugate, optionally in further combination with an endocrine therapy agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.

The present invention relates to methods of treating breast cancer using selective estrogen receptor degradation agents (SERD). The present specification relates to methods of treating hormone receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2-), metastatic, or localized region recurrent breast cancer comprising administering to a patient suffering from such cancer a next generation selective estrogen receptor degrading agent (ngSERD), such as carmistrant, such as carmistrant. Characterized in that the cancer has relapsed or progressed after at least one past endocrine treatment line.

Provided herein are methods of determining sensitivity to dose intense chemotherapy regimens based upon an index of estrogen receptor (ER)- and progesterone receptor (PR)-related genes, referred to as the sensitivity to endocrine therapy index (SETER / PR index). Further provided are methods of treating cancer patients determined to be sensitive to dose intense chemotherapy therapy by the SETER / PR index. Also provided herein are methods for determining prognosis based on the SET2,3 index.

The present disclosure relates to adjuvant treatment of HR + / HER2-phase II or III early breast cancer in adult patients. The methods comprise administering a rebosilil (CDK4 / 6 inhibitor) in combination with endocrine therapy.

To provide a medicament for treating estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), and estrogen receptor 1 mutant (ESR1 m) breast cancer.SOLUTION: A medicament comprises a compound of the following formula, or a pharmaceutically acceptable salt thereof, in which the compound or the pharmaceutically acceptable salt thereof is used such that it is administered to a patient in need of such treatment at a dose of about 400 mg at least once a day for at least one week, the patient having previously received endocrine therapy.SELECTED DRAWING: None

The present invention refers to the in vitro use of DNA copy number alterations (CNAs) for predicting the response of patients with HR+ / HER2− breast cancer to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy; for the prognosis of patients with HR+ / HER2− breast cancer, for monitoring patients with HR+ / HER2− breast cancer, or for classifying patients with HR+ / HER2− breast cancer into responder or non-responder to a treatment comprising targeted therapy, such as CDK4 / 6 inhibitors, and / or endocrine therapy.

The application discloses a kind of multiple targeting photothermal-photo dynamic-endocrine three-mode synergistic treatment breast cancer nano-drug and its application, it is related to biological and new pharmaceutical technical field.The application is effectively inhibited the growth and metastasis of breast cancer cell by the three-mode synergistic effect of photothermal, photo dynamic and endocrine therapy, amphiphilic polymer based on Tcpp (four carboxyl phenyl porphyrin) It can be self-assembled to form nanoscale hollow regular sphere, using the high permeability and retention effect (EPR effect) of tumor site, realize the efficient accumulation of drug in tumor tissue;Prodrug BHP is realized by combining photothermal group and palbociclib, and the synergistic effect of multiple action mechanisms, so as to improve the treatment effect.The nano-drug prepared by the application has good safety and biocompatibility, and exhibits significant antitumor effect in tumor-bearing nude mouse model, which provides a new strategy and idea for the treatment of breast cancer.

Methods of predicting treatment benefit for reducing risk of recurrence for breast cancer is provided. In some embodiments, a method can include providing a breast tissue sample from a subject with invasive, hormone receptor (HR)-positive, HER2-negative breast cancer; analyzing the breast tissue sample for a biosignature comprising at least the biomarkers GLUT1 and Ki67 or at least the biomarkers PR and FOXA1, where the analyzed biosignature predicts the benefit from a breast cancer treatment with adjuvant therapy (e.g., radiotherapy followed by endocrine therapy) to reduce the risk of breast cancer recurrence in the subject. In some embodiments, the method includes administering the breast cancer treatment with adjuvant therapy to the subject.